TherapeuticsMD (TXMD) reported a strong third quarter with net revenues that came in at the upper end of TherapeuticsMD Q3 guidance. The company's FDA approved products demonstrated impressive numbers in both sales and script growth, which demonstrates the company's ability to simultaneously launch three commercial products (Figure 1).
Figure 1: Q3 Overview (Source: TXMD)
I believe the Q3 earnings not only illustrates the company's commercial strength, but it also provides me with some confidence they will be able to carry this momentum into 2020 and finally start delivering for its shareholders.